Inspyr Therapeutics, Inc. (NSPX)
|Net Income (ttm)||-26.27M|
|Trading Day||July 22|
|Day's Range||0.0062 - 0.0069|
|52-Week Range||0.0005 - 0.0718|
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021...
Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.
|Stock Exchange |
|Ticker Symbol |